Comparison of felodipine and enalapril monotherapy in essential hypertension

Richard W. Watts, Angela Dufek, Lindon M.H. Wing

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

This study compared the efficacy and tolerability of monotherapy with felodipine and enalapril in patients with essential hypertension using a double-blind randomised crossover design. Thirty-five subjects (22 male, 13 female-ages: median 48 years, range 31-69 years) entered the randomised phases of the study and 32 subjects completed the study. Following a 4-week run-in placebo phase, the treatments were felodipine ("Plendil ER" 5-20 mg and enalapril 5-20 mg orally once daily for 8 weeks, each with matching placebos. Dose titration was at 2 and/or 4 weeks in each phase. Number of subjects with each different end-of-phase dose were for felodipine: 5 mg-8, 10 mg-11, 20 mg-13 and enalapril: 5 mg-6, 10 mg-9, 20 mg-17. Predose supine blood pressure (mean SEM) was reduced in both active treatment phases compared wih the run-in phase (159 ±2/101 ± 1), but there was no significant difference in blood pressure between the active phases: felodipine 143±2/90±1 and enalapril 146±2/92±1. The most common adverse effects were for felodipine: headache, flushing, ankle swelling; and for enalapril: cough. Felodipine and enalapril as once daily monotherapy are thus of similar antihypertensive efficacy but with predictably different adverse effect profiles.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalBlood Pressure
Volume2
Issue number1
DOIs
Publication statusPublished - 1 Jan 1993
Externally publishedYes

Keywords

  • Angiotensin-converting enzyme inhibitors
  • Calcium channel blockers
  • Enalapril
  • Felodipine
  • Hypertension

Fingerprint Dive into the research topics of 'Comparison of felodipine and enalapril monotherapy in essential hypertension'. Together they form a unique fingerprint.

Cite this